Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer

Leena Kankaanranta, Tiina Seppälä, Hanna Koivunoro, Kauko Saarilahti, Timo Atula, Juhani Collan, Eero Salli, Mika Kortesniemi, Jouni Uusi-Simola, Antti Mäkitie, Marko Seppänen, Heikki Minn, Petri Kotiluoto, Iiro Auterinen, Sauli Savolainen, Mauri Kouri, Heikki Joensuu (Corresponding Author)

    Research output: Contribution to journalArticleScientificpeer-review

    101 Citations (Scopus)

    Abstract

    Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

    Original languageEnglish
    Pages (from-to)475-482
    JournalInternational Journal of Radiation Oncology Biology Physics
    Volume69
    Issue number2
    DOIs
    Publication statusPublished - 1 Oct 2007
    MoE publication typeA1 Journal article-refereed

    Fingerprint

    Boron Neutron Capture Therapy
    Head and Neck Neoplasms
    therapy
    boron
    cancer
    neutrons
    tumors
    Neck
    Therapeutics
    Head
    Carcinoma
    Xerostomia
    Neoplasms
    Mucositis
    Boron
    National Cancer Institute (U.S.)
    Deglutition Disorders
    irradiation
    Fructose
    pain

    Keywords

    • Boron neutron capture therapy
    • Boronophenylalanine
    • Head and neck cancer
    • Positron emission tomography
    • Radiotherapy

    Cite this

    Kankaanranta, L., Seppälä, T., Koivunoro, H., Saarilahti, K., Atula, T., Collan, J., ... Joensuu, H. (2007). Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 69(2), 475-482. https://doi.org/10.1016/j.ijrobp.2007.03.039
    Kankaanranta, Leena ; Seppälä, Tiina ; Koivunoro, Hanna ; Saarilahti, Kauko ; Atula, Timo ; Collan, Juhani ; Salli, Eero ; Kortesniemi, Mika ; Uusi-Simola, Jouni ; Mäkitie, Antti ; Seppänen, Marko ; Minn, Heikki ; Kotiluoto, Petri ; Auterinen, Iiro ; Savolainen, Sauli ; Kouri, Mauri ; Joensuu, Heikki. / Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 69, No. 2. pp. 475-482.
    @article{924846a0d2a04304b86c0576698f512e,
    title = "Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer",
    abstract = "Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83{\%}) patients responded to BNCT, and 2 (17{\%}) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33{\%}) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.",
    keywords = "Boron neutron capture therapy, Boronophenylalanine, Head and neck cancer, Positron emission tomography, Radiotherapy",
    author = "Leena Kankaanranta and Tiina Sepp{\"a}l{\"a} and Hanna Koivunoro and Kauko Saarilahti and Timo Atula and Juhani Collan and Eero Salli and Mika Kortesniemi and Jouni Uusi-Simola and Antti M{\"a}kitie and Marko Sepp{\"a}nen and Heikki Minn and Petri Kotiluoto and Iiro Auterinen and Sauli Savolainen and Mauri Kouri and Heikki Joensuu",
    year = "2007",
    month = "10",
    day = "1",
    doi = "10.1016/j.ijrobp.2007.03.039",
    language = "English",
    volume = "69",
    pages = "475--482",
    journal = "International Journal of Radiation Oncology Biology Physics",
    issn = "0360-3016",
    publisher = "Elsevier",
    number = "2",

    }

    Kankaanranta, L, Seppälä, T, Koivunoro, H, Saarilahti, K, Atula, T, Collan, J, Salli, E, Kortesniemi, M, Uusi-Simola, J, Mäkitie, A, Seppänen, M, Minn, H, Kotiluoto, P, Auterinen, I, Savolainen, S, Kouri, M & Joensuu, H 2007, 'Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer', International Journal of Radiation Oncology Biology Physics, vol. 69, no. 2, pp. 475-482. https://doi.org/10.1016/j.ijrobp.2007.03.039

    Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. / Kankaanranta, Leena; Seppälä, Tiina; Koivunoro, Hanna; Saarilahti, Kauko; Atula, Timo; Collan, Juhani; Salli, Eero; Kortesniemi, Mika; Uusi-Simola, Jouni; Mäkitie, Antti; Seppänen, Marko; Minn, Heikki; Kotiluoto, Petri; Auterinen, Iiro; Savolainen, Sauli; Kouri, Mauri; Joensuu, Heikki (Corresponding Author).

    In: International Journal of Radiation Oncology Biology Physics, Vol. 69, No. 2, 01.10.2007, p. 475-482.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer

    AU - Kankaanranta, Leena

    AU - Seppälä, Tiina

    AU - Koivunoro, Hanna

    AU - Saarilahti, Kauko

    AU - Atula, Timo

    AU - Collan, Juhani

    AU - Salli, Eero

    AU - Kortesniemi, Mika

    AU - Uusi-Simola, Jouni

    AU - Mäkitie, Antti

    AU - Seppänen, Marko

    AU - Minn, Heikki

    AU - Kotiluoto, Petri

    AU - Auterinen, Iiro

    AU - Savolainen, Sauli

    AU - Kouri, Mauri

    AU - Joensuu, Heikki

    PY - 2007/10/1

    Y1 - 2007/10/1

    N2 - Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

    AB - Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

    KW - Boron neutron capture therapy

    KW - Boronophenylalanine

    KW - Head and neck cancer

    KW - Positron emission tomography

    KW - Radiotherapy

    UR - http://www.scopus.com/inward/record.url?scp=34548494642&partnerID=8YFLogxK

    U2 - 10.1016/j.ijrobp.2007.03.039

    DO - 10.1016/j.ijrobp.2007.03.039

    M3 - Article

    C2 - 17689034

    AN - SCOPUS:34548494642

    VL - 69

    SP - 475

    EP - 482

    JO - International Journal of Radiation Oncology Biology Physics

    JF - International Journal of Radiation Oncology Biology Physics

    SN - 0360-3016

    IS - 2

    ER -